Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GP MDI · 1 trial · 1 indication
Evaluate the effect of 2 different GP MDI doses relative to placebo MDI as an add-on treatment to BFF MDI on lung function in 4 to less than 12 years old participants with asthma.
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence ABC | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment A, Treatment B followed by Treatment C for 3 weeks each. |
| Treatment Sequence BCA | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment B, Treatment C followed by Treatment A for 3 weeks each. |
| Treatment Sequence CAB | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment C, Treatment A followed by Treatment B for 3 weeks each. |
| Treatment Sequence ACB | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment A, Treatment C followed by Treatment B for 3 weeks each. |
| Treatment Sequence BAC | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment B, Treatment A followed by Treatment C for 3 weeks each. |
| Treatment Sequence CBA | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment C, Treatment B followed by Treatment A for 3 weeks each. |
| Name | Type | Description |
|---|---|---|
| GP MDI | COMBINATION_PRODUCT | GP MDI will be administered via oral inhalation twice daily (BID). |
| BFF MDI | COMBINATION_PRODUCT | BFF MDI will be administered via oral inhalation BID. |
| Placebo MDI | COMBINATION_PRODUCT | Placebo MDI will be adminsitered via oral inhalation BID. |
Main Inclusion Criteria: * Participants who have a documented history of physician-diagnosed asthma * Participants who have been using a stable and regular inhaled corticosteroid plus one additional asthma controller medication. * Participants must have a Childhood Asthma Control Test score ≥ 19. *...
GP MDI is an investigational small molecule being developed for the treatment of asthma. It is currently being studied in pediatric patients aged 4 to less than 12 years with asthma, as part of a Phase 2 clinical trial.
GP MDI is a combination product that includes inhaled glycopyrronium, a bronchodilator, taken together with BFF. It is being studied to investigate lung function in children with asthma.
GP MDI is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN.
GP MDI is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities.
GP MDI is being studied in a Phase 2 trial with the identifier NCT07525375. This randomized, double-blind, controlled study is investigating lung function with two different doses of inhaled glycopyrronium taken with BFF compared to BFF alone in children aged 4 to less than 12 years with asthma.
GP MDI is a combination product that includes inhaled glycopyrronium, which is a bronchodilator, taken together with BFF. It is not the same as glycopyrronium alone, as it is being studied as a fixed-dose combination.